Abstracts tagged "B cells"

Abstract Number: 859 • 2014 ACR/ARHP Annual Meeting
TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses
Tomohisa Okamura¹, Kaoru Morita¹, Mariko Inoue¹, Toshihiko Komai¹, Yukiko Iwasaki¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Hirofumi Shoda², Keishi Fujio² and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production and associated with a wide range of clinical manifestations. Recent case-control association…
Abstract Number: 2691 • 2014 ACR/ARHP Annual Meeting
A Novel CD123^–CD11c^– Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus
Satoshi Kubo¹, Shingo Nakayamada¹, Naoki Yunoue¹, Maiko Yoshikawa¹, Kunihiro Yamaoka¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overproduction of autoantibodies by B cells and breaking self-tolerance of T cells and dendritic…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 858 • 2014 ACR/ARHP Annual Meeting
ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets
Li Chun Wang¹, Stuart Perper¹, Annette Schwartz², Christian Goess³, Liz O'connor⁴, Dawna Hartman², Candace Graff², Andrew Souers⁵, Joel Leverson⁵, Steven Elmore⁵ and Lisa Olson², ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, North Chicago, IL
Background/Purpose Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. Navitoclax, a selective inhibitor of both BCL-2 and BCL-X(L) demonstrated…
Abstract Number: 2185 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2
Brendan M. Giles¹ and Susan A. Boackle², ¹University of Colorado School of Medicine, Aurora, CO, ²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: We have recently identified a variant in intron 1 of complement receptor 2 (CR2/CD21) that is associated with decreased risk of lupus (rs1876453; Pmeta=4.2×10-4,…
Abstract Number: 1718 • 2014 ACR/ARHP Annual Meeting
B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis
Sébastien Sanges^1,2,3, Niloufar Kavian⁴, Carine Hauspie^1,3,5, Carole Nicco⁴, Thomas Guerrier^1,3, Virginie Dutoit-Lefèvre^1,3, Guillaume Lefèvre^1,2,5,6, Alexandra Forestier^1,2,3, Vincent Sobanski^1,2,6, Christelle Faveeuw⁷, Myriam Labalette^1,3,5, Frédéric Batteux⁴, David Launay^1,2,3 and Sylvain Dubucquoi^1,3,5, ¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³EA 2686, Lille, Lille, France, ⁴Université Paris Descartes, EA 1833, Hôpital Cochin, AP-HP, Paris, Paris, France, ⁵Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, ⁶EA 2686, Lille, LILLE, France, ⁷Institut National de la Santé et de la Recherche Médicale Unité 547, Institut Pasteur de Lille, Institut Fédératif de Recherche 142, Université de Lille Nord de France, Lille, France
Background/Purpose Systemic sclerosis (SSc) is a multi-organ fibrotic disease associated with auto-immune abnormalities. Several clinical and experimental observations suggest that B cells are involved in…
Abstract Number: 756 • 2014 ACR/ARHP Annual Meeting
Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells
Ayumi Yoshizaki¹, Yoshihide Asano², Takashi Taniguchi¹, Ryosuke Saigusa¹, Kouki Nakamura¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Zenshiro Tamaki¹, Miki Miyazaki¹ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose Nucleosome is the basic repeating units of chromatin. Each nucleosome is composed of an inner core of histones H3 and H4 and an outer…
Abstract Number: 1951 • 2014 ACR/ARHP Annual Meeting
A Novel CD27^(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE
Sarah Fleischer¹, Claudia Giesecke¹, Henrik Mei¹, Peter E. Lipsky², Capucine Daridon³ and Thomas Dörner³, ¹Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany, Berlin, Germany, ²Peking Union Medical College Hospital, Beijing, China, ³CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease known to be associated with a breakdown of self-tolerance, B-cell hyperactivity and disturbed B-cell homeostasis of…
Abstract Number: 1623 • 2014 ACR/ARHP Annual Meeting
Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus
Julie Ducreux¹, Séverine Nieuwland², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Institut de Recherche Expérimentale et Clinique, Pôle de pathologies rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: systemic lupus erythematosus (SLE) is characterized by a break of tolerance to autoantigens, and polyclonal activation of B cells. We performed multicolor flow cytometry…
Abstract Number: 662 • 2014 ACR/ARHP Annual Meeting
Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus
Amanda Watkins¹, Ramon Bonegio², Guneet Kochar¹, Gabriella Wilson¹, Bari Laskow¹, Christophe Richez¹, Ian Rifkin¹ and Kei Yasuda³, ¹Boston University School of Medicine, Boston, MA, ²Renal, Boston University School of Medicine, Boston, MA, ³Medicine, Boston University School of Medicine, Boston, MA
Background/Purpose Interferon regulatory factor 5 (IRF5) polymorphisms are strongly associated with an increased risk of developing Systemic Lupus Erythematosus (SLE). SLE is caused, in part,…
Abstract Number: 1950 • 2014 ACR/ARHP Annual Meeting
Circulating CD19⁺CD38⁺CD43⁺ B Cell Subset in SLE Patients Have More Cell Cycle Related Genes Than Healthy Controls
Hiroshi Fujii¹, Tomoaki Machiyama¹, Kanae Akita², Yukiko Kamogawa¹, Ryu Watanabe¹, Yoko Fujita³, Yuko Shirota⁴, Shinichiro Saito⁵, Tomonori Ishii⁶ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ²Department of Heatology and Rheumatology, Tohoku University, Sendai, Japan, ³Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁴Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of hematology and rheumatology, Tohoku University, Sendai, Japan, ⁶Seiryouchou Aobaku, Tohoku University, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with deposition of autoantibodies such as anti DNA antibody. After activation of B cells…
Abstract Number: 1640 • 2014 ACR/ARHP Annual Meeting
Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Manabu Kawamoto¹, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose . B cell activating factor of tumor necrosis factor family (BAFF) is a positive regulator of B cell function and expressed in dendritic cells,…
Abstract Number: 643 • 2014 ACR/ARHP Annual Meeting
The Effect of TNF Inhibition on the Autoreactive B Cell Repertoire in SLE Prone Mice
Anne Davidson, Weiqing Huang and Ranjit Sahu, Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: TNF inhibitors are widely used for inflammatory diseases but often induce ANAs that sometimes progress to overt SLE. TNF deficient mice fail to generate…
Abstract Number: 1948 • 2014 ACR/ARHP Annual Meeting
A Dual Role for IFN-γ in Development of Peripheral B Cells in Lupus-Prone MRL/Lpr Mice
Takeshi Machida¹, Natsumi Sakamoto¹, Gary S. Gilkeson² and Hideharu Sekine¹, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: It had been reported previously that IFN-gamma and IFN-gamma-receptor-1 (IFNGR1) were required for auto-Ab production and development of renal disease in lupus-prone MRL/lpr mice.…
Abstract Number: 1607 • 2014 ACR/ARHP Annual Meeting
B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou² and Mary K. Crow³, ¹Research, HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose Lupus flare reflects an increase of disease activity that is associated with significant morbidity and accumulation of tissue damage. Prediction and prevention of lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].